512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies
Rahul Aggarwal, Sarah E. Umetsu, Mallika Dhawan, Jennifer A. Grabowsky, Julia Carnevale, Michael Howell, Lauren Wilch, Jocelyn Chapman, Edwin Alvarez, Susan Calabrese, Simon A. Smith, Neelam Shah, Emma Dean, Pamela N. Münster, Eric A. Collisson
Topics & Concepts
InterimMedicineARID1ASolid tumorInterim analysisCancer researchOncologyInternal medicineCancerClinical trialMutationGeneticsLawGenePolitical scienceBiologyChromatin Remodeling and CancerMelanoma and MAPK PathwaysPARP inhibition in cancer therapy